prostate cancer

FDA panel votes against Xgeva for prostate cancer

FDA panel votes against Xgeva for prostate cancer

Yahoo/AP

Can Amgen Convince Docs to Recommend Xgeva Approval?

Can Amgen Convince Docs to Recommend Xgeva Approval?

Motley Fool

FDA questions benefit of Amgen's bone drug for new use in prostate cancer patients

FDA questions benefit of Amgen's bone drug for new use in prostate cancer patients

Yahoo/AP

Amgen risk/reward attractive into Xgeva panel, says Deutsche Bank

Amgen risk/reward attractive into Xgeva panel, says Deutsche Bank

Yahoo/Fly on the Wall

J&J’s Zytiga for Prostate Cancer Too Expensive, U.K. Cost Agency Says

J&J’s Zytiga for Prostate Cancer Too Expensive, U.K. Cost Agency Says

Bloomberg

Medivation says prostate cancer pill MDV3100 met goal in second clinical trial

Medivation says prostate cancer pill MDV3100 met goal in second clinical trial

Yahoo/AP

Dendreon And Provenge's True Median Life-Extension Benefit

Dendreon And Provenge's True Median Life-Extension Benefit

Seeking Alpha

Dendreon's Provenge And JNJ's Zytiga Both Had Strong Early Sales

Dendreon's Provenge And JNJ's Zytiga Both Had Strong Early Sales

Seeking Alpha

Dendreon: Following Up On Market Mania

Dendreon: Following Up On Market Mania

Seeking Alpha

Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data

Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data

TheStreet.com